COMPLIANCE WITH THE REQUIREMENTS OF GMP and GDP IS PROVED
SANTO obtained three important certificates of compliance of its production sites manufacturing injectable solutions and infusions, and solid oral medicines with the good manufacturing practice (GMP), as well as a certificate of compliance of its pharmaceutical warehouse with the good distribution practice (GDP).
Obtainment of those certificates is a significant proof that the quality system and production conditions at SANTO guarantee high standards of medicines manufactured.
It should be reminded that the GMP (Good Manufacturing Practice) sets out the general requirements to the production of medicines, quality control, and maintenance of documents, as well as to the staff, premises and equipment. GDP (Good Distribution Practice) is a system of quality assurance for warehouses and distribution centers involved in circulation of medicines throughout the supply chain, beginning with the delivery of raw materials to production facilities, ending with the shipment of finished products to end users.
“I am proud of another achievement of the Company - obtainment of certificates in respect to our production sites, including a new workshop for the production of solid oral medicines and our pharmaceutical warehouse.” – General Director of SANTO Jiri Urbanec says, - “This is certainly the result of the successful teamwork. And, of course, a convincing proof that we do our best to ensure that patients can receive an effective treatment of proper quality. Currently, the medicines manufactured by the Company are used in cardiology, gastroenterology, allergology, dermatology, neurology, gynecology, urology, pediatrics, ophthalmology, pulmonology, and otorhinolaryngology. We manufacture antibiotics as well. We love our country and care about the health of Kazakhstani people!”
“It was a great pleasure to read the news about new certificates obtained by our company. For over 6 years we have been paying great attention to the upgrading of the plant in Shymkent. We have invested in infrastructure, manufacturing equipment, but first of all, in training of employees in world-class standards. SANTO plant took another step to become the most modern plant in Central Asia. Those certificates confirm the commitment, professional competence and capability of the SANTO staff of working in compliance with the highest standards. We are proud of the value we bring to Kazakhstani patients and SANTO's contribution to the general development of Polpharma,” said Mr. Jerzy Starak, Chairman of the Polpharma group's Supervisory Board.
------------------------------------------------------------------------------------------------------------------------------------------
ABOUT SANTO:
SANTO Member of Polpharma Group is a trade mark of Chimpharm JSC (KASE: CHFM). The Company develops, manufactures and delivers affordable medicines of high quality to the markets of Kazakhstan and Central Asia. Production capacities of the Company allow manufacturing 600 million tablets, 300 million ampoules, 6 million infusion bottles, 40 million bottles of antibiotics, and 26 million bottles of syrups per year. The Company is a leader in the pharmaceutical market of Kazakhstan with a portfolio including more than 200 generics in 12 therapeutic categories for the treatment of diseases in various fields of therapy. SANTO is a responsible employer for over 1000 individuals in Shymkent and in all regions of Kazakhstan. The Company increases exports of its products to Turkmenistan, Kyrgyzstan, Mongolia, Tajikistan, Russia and Ukraine.
Tatyana Filipchik, PR Manager
SANTO
Address: 17/1 Al-Farabi Ave., Nurly Tau PFC, 5B block, 19th floor, 050013, Almaty, Kazakhstan
Phone: +7 (727) 3121833
e-mail: tatyana.filipchik@santo.kz